Cargando…
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
BACKGROUND: The role of MET amplification in lung cancer, particularly in relation to checkpoint inhibition and EGFR WT, has not been fully explored. In this study, we correlated PD-L1 expression with MET amplification and EGFR, KRAS, or TP53 mutation in primary lung cancer. METHODS: In this retrosp...
Autores principales: | Albitar, Maher, Sudarsanam, Sucha, Ma, Wanlong, Jiang, Shiping, Chen, Wayne, Funari, Vincent, Blocker, Forrest, Agersborg, Sally |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862607/ https://www.ncbi.nlm.nih.gov/pubmed/29568386 http://dx.doi.org/10.18632/oncotarget.24455 |
Ejemplares similares
-
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018) -
Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
por: Ma, Wanlong, et al.
Publicado: (2017) -
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
por: Batenchuk, Cory, et al.
Publicado: (2018) -
TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer
por: Li, Jia, et al.
Publicado: (2021) -
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)